摘要
目的:探讨厄贝沙坦联合环磷酰胺对肾病综合征患者T淋巴细胞亚群及细胞因子的影响。方法:选取2017年6月-2018年6月笔者所在医院收治的肾病综合征患者136例,随机分为两组,对照组应用环磷酰胺治疗,研究组应用厄贝沙坦联合环磷酰胺治疗。比较两组治疗前、后T淋巴细胞亚群、细胞因子水平、不良反应及临床疗效。结果:治疗前两组T淋巴细胞亚群水平对比,差异均无统计学意义(P>0.05);治疗后研究组CD8^+低于对照组,CD3^+、CD4^+、CD4^+/CD8^+均高于对照组(P<0.05);治疗前两组细胞因子水平对比,差异均无统计学意义(P>0.05);治疗后研究组IL-1、IL-6、IL-8、TNF-α均低于对照组(P<0.05);研究组不良反应发生率低于对照组(P<0.05);研究组总有效率高于对照组(P<0.05)。结论:厄贝沙坦联合环磷酰胺对于改善肾病综合征患者T淋巴细胞亚群及细胞因子水平效果理想,临床上应进一步推广应用。
Objective:To investigate the effects of Irbesartan combined with Cyclophosphamide on T lymphocyte subsets and cytokines of patients with nephrotic syndrome.Method:A total of 136 patients with nephrotic syndrome admitted to our hospital from June 2017 to June 2018 were randomly divided into two groups.The control group was treated with Cyclophosphamide.The study group was treated with Irbesartan combined with Cyclophosphamide.The levels of T lymphocyte subsets and cytokines before and after treatment,adverse reactions and clinical efficacy were compared between the two groups.Result:Before treatment,the levels of T lymphocyte subsets in the two groups were compared,and the differences were not statistically significant(P>0.05).After treatment,CD8+of the study group was lower than that of the control group,CD3^+,CD4^+,CD4^+/CD8^+were higher than those of the control group(P<0.05).Before treatment,the levels of cytokines in the two groups were compared,and the differences were not statistically significant(P>0.05).After treatment,IL-1,IL-6,IL-8 and TNF-αof the study group were lower than those of the control group(P<0.05).The incidence of adverse reactions in the study group was lower than that of the control group(P<0.05).The total effective rate of the study group was higher than that of the control group(P<0.05).Conclusion:Irbesartan combined with Cyclophosphamide is effective in improving T lymphocyte subsets and cytokines levels in patients with nephrotic syndrome,and it should be further promoted and applied clinically.
作者
刘云霞
LIU Yunxia(Gucheng County Chinese Medicine Hospital,Gucheng 441700,China)
出处
《中外医学研究》
2019年第36期145-147,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
